文献速递淋巴瘤造血干细胞移植与细胞治疗

异基因干细胞移植作为套细胞淋巴瘤一线治疗的一部分

Allogeneic stem cell transplantation as part of front line therapy for Mantle cell lymphoma.
PubMed 文献 · Br J Haematol · 2018-12-17

这项多中心前瞻性试验评估了25例年轻套细胞淋巴瘤患者在一线治疗中接受BEAM-Campath方案预处理异基因干细胞移植的可行性。中位随访60.5个月,2年无进展生存率和总生存率分别为68%和80%,5年分别为56%和76%,9例(38%)发生急性移植物抗宿主病,14例(58%)发生慢性移植物抗宿主病。作者认为一线异基因干细胞移植可行,但仅应考虑用于常规治疗后早期进展高风险的患者。

要点

  • 25例年轻套细胞淋巴瘤患者一线接受BEAM-Campath预处理异基因移植,24例植入成功,100天内无非复发死亡事件。
  • 中位随访60.5个月,2年无进展生存率68%、总生存率80%,5年分别为56%和76%。
  • 9例(38%)发生急性GVHD,14例(58%)发生慢性GVHD(其中8例为广泛型)。

核心结论

  • 一线异基因干细胞移植可行,但仅应考虑用于常规治疗后早期进展高风险的患者。

研究设计与样本

  • 多中心前瞻性试验,25例年轻套细胞淋巴瘤患者在一线治疗中接受异基因干细胞移植。
  • 预处理方案为BEAM(卡莫司汀、依托泊苷、阿糖胞苷、美法仑)-Campath,供者包括同胞供者和无关供者,诱导治疗采用宽松策略。

主要发现

  • 25例中24例植入成功,100天内无非复发死亡事件。
  • 中位随访60.5个月,共6例死亡,其中3例死于套细胞淋巴瘤。
  • 2年无进展生存率和总生存率分别为68%和80%,5年分别为56%和76%。
  • 同胞移植与无关供者移植的无进展生存率非常相似,移植前缓解状态不同的患者之间无进展生存率无差异。
  • 9例(38%)发生急性移植物抗宿主病,14例(58%)发生慢性移植物抗宿主病,其中8例为广泛型。

临床怎么用

  • 作者认为一线异基因干细胞移植可行,但仅应考虑用于常规治疗后早期进展高风险的患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Mantle cell lymphoma (MCL) is an aggressive form of non-Hodgkin lymphoma that remains incurable for the majority of patients. Allogeneic stem cell transplantation (alloSCT) produces long-term disease-free remissions for around 30-40% patients, however it is reserved for the treatment of relapsed disease. This study examined the use of front line transplantation for young patients in an attempt to improve outcomes. Twenty-five patients received an alloSCT using BEAM [BCNU (carmustine), etoposide, cytarabine, melphalan)-Campath conditioning following permissive induction therapy from both related and unrelated donors. This was a multi-centre prospective trial. Twenty-four of 25 patients engrafted with no non-relapse mortality events by day 100. With a median follow-up of 60·5 months, there have been six deaths (3 from MCL). The progression-free survival (PFS) and overall survival were 68% and 80% at 2 years and 56% and 76% at 5 years. PFS was very similar for both sibling and unrelated transplants and there was no difference in PFS between patients with respect to remission status prior to transplantation. Nine (38%) patients experienced acute graft-versus-host disease (GVHD) and 14 (58%) experienced chronic GVHD, of which 8 were extensive. Front line alloSCT is feasible but should only be considered for patients at high risk of early progression following conventional therapy.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Rule S, Cook G, Russell NH, et al. Allogeneic stem cell transplantation as part of front line therapy for Mantle cell lymphoma. Br J Haematol. 2018. PMID: 30560573. doi:10.1111/bjh.15723

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。